Cefotetan Therapy for Escherichia Coli Infections
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorOregon Health and Science University
About this trial
This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia or genitourinary infections caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum concentrations.
Eligibility criteria
Qualifiers
Identified within 48 hours of inpatient antibiotic administration for acute illness.
Patient or legally authorized representative are able to provide informed consent for participation in the study.
Monomicrobial E. coli bacteremia with a genitourinary source.
Isolate susceptible to both ertapenem and cefotetan (ESBL infections) or ceftriaxone and cefotetan (non-ESBL infections).
Disqualifiers
Allergy to cefotetan.
History of cephalosporin-associated hemolytic anemia.
Allergy to ertapenem or meropenem (among patients with ESBL E. coli infections).
Allergy to ceftriaxone (among patients with non-ESBL E. coli infections). Includes allergy to antibiotics with a similar structure expected to confer cross reactivity to ceftriaxone (cefotaxime, cefpodoxime, ceftazidime).
Trial design
Treatments tested in this trial
- Cefotetan
- Carbapenems
- Beta Lactam Antibiotics
Treatment groups
84 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov